Shares of Akero Therapeutics, Inc. (AKRO) are gaining over 17% on Monday after the company announced statistically significant histological improvements at week 96 in phase 2b Harmony study.AKRO is currently trading at $32.65, up $4.84 or 17.42%, on the Nasdaq. The stock opened its trading at $35.51 after closing Friday at $27.81.

Akero Therapeutics，Inc.（AKRO）的股价周一上涨逾17%，此前该公司在2b期和谐研究的第96周宣布了统计学上显着的组织学改善。阿克罗目前在纳斯达克的交易价格为32.65美元，上涨4.84美元，涨幅17.42%。该股周五收于27.81美元，开盘价为35.51美元。

The stock has traded between $11.25 and $58.38 in the past 52-week period.Harmony is a Phase 2b study evaluating the efficacy and safety of the company's lead product candidate efruxifermin in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, fibrosis stage 2 or 3..

该股在过去52周的交易价格在11.25美元至58.38美元之间。Harmony是一项2b期研究，评估该公司主要产品候选依氟昔芬对肝硬化前代谢功能障碍相关脂肪性肝炎，纤维化2或3期患者的疗效和安全性。。

The company said efruxifermin-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis of patients with week 96 biopsies.Andrew Cheng, CEO of Akero, said: 'Today's results show that longer exposure to EFX has the potential to yield sustained fibrosis improvement as well as widening anti-fibrotic treatment responses across the treated patient populations.' For comments and feedback contact: editorial@rttnews.comBusiness News.

该公司表示，通过ITT分析以及对96周活组织检查患者的初步分析，接受efruxifermin治疗的患者在几乎所有组织学终点上都有统计学上的显着改善。Akero首席执行官安德鲁·程（AndrewCheng）说：“今天的研究结果表明，长期接触EFX有可能产生持续的纤维化改善，并扩大治疗患者群体的抗纤维化治疗反应。”如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Get Access to Premium Stock Alerts with RTT Biotech Investor.

通过RTT Biotech Investor访问溢价股票警报。

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股